Source: Chasing Markets
Sponsored Content By: Resultz Media
The marijuana revolution is in full swing and 2019 will go down as another incredible year of growth for marijuana stocks.
The next company that may land in the spotlight could be Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN), a medical marijuana pharmaceutical company that is focusing on repairing vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1).
In October 2018, Resinco Capital acquired 49% of UK based pharma company ReFormation Pharmaceuticals in an all stock deal with the option to exercise future warrants. Rescino is a global investment company looking to expand into the cannabis/pharma sector.
The growth of the marijuana industry has been very rapid in the last two years. Since 2016, marijuana has been legalized in over 29 states. Support for marijuana legislation in the U.S. is also at its highest ever according to the latest Gallup poll.
Tilray, a Canadian pharmaceutical and cannabis company, made its debut on the NASDAQ this summer and soared from around $20 to as high as $300. Medical marijuana company Canopy Growth went from under $25 in August to over $52 in September, more than doubling.
Traders were celebrating the fact that the maker of Corona beer decided to invest a whopping $4 billion into the company. If that isn’t confidence in the future of the marijuana industry, then what is?
Pot stocks may have experienced a healthy pullback recently after Canada legalized recreational marijuana on October 17th, but the gains have still been incredible this year and what could still be expected may blow these gains out of the water. Grand View Research has predicted that the global legal marijuana market is expected to reach a staggering $146.4 billion by end of 2025.
Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN), has been developing a new concept: that the body’s own stem cells that induce repair of tissues can be made to function more efficiently. This is very exciting and is something that could really shake up the medical arena.
Over the years, research after research has shown that marijuana is beneficial in the treatment of many conditions which include cancer, multiple sclerosis, epilepsy, arthritis, anxiety, IBS, and PTSD.
Epidiolex, the very first FDA-approved cannabis-based drug just became available in the U.S. at the start of November. When it gained FDA approval this past summer, it was a validation that the world is now ready for cannabinoid medicine.
The company is led by world class scientist, CEO and CSO, Professor Jagdeep Nanchahal, of the University of Oxford. Signals that the body’s own stem cells that induce repair of tissues can be made to function more efficiently, have been identified by Prof. Nanchahal’s team.
Ground breaking research by the company’s founders has led to the discovery of an endogenous molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury.
The global stem cells market was worth $5.17 billion in 2017 and is projected to grow to $9.03 billion by 2023. Stem cell therapy has become the standard of care for many blood disorders, but cellular therapy for solid organs has not yet yielded the anticipated benefits.
Prof. Nanchahal’s work on complex fractures has led to the identification of a highly conserved physiological pathway whereby a protein released by damaged cells accelerates repair and regeneration of multiple tissues.
Administration of only a single dose of the protein is effective across a range of disorders by targeting the body’s own stem cells.
Administration of this protein to mice with injuries has been shown to speed up the healing of bone fractures, restoration of blood formation in bone marrow after chemotherapy, and repair of damaged skeletal muscle.
This is a disruptive technology which will deliver a first in class therapeutic!
The company will be controlling inflammation first, and then helping the stem cells to repair the damaged tissues. For controlling inflammation, the company will use synthetic non-psychoactive cannabinoids and will access the next generation product from CannBioRex to assess the efficacy of combination therapy in its mouse model.
The repair of major tissues will be another benefit of properly researching and developing the medical activities of cannabis-based products.
The Company’s research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists.
As data accrues, the company will be filing patent applications that are licensed from the University of Oxford for the various clinical conditions that the company is testing in animal models. The company already has preliminary data for myocardial infarction (heart attack) and are starting experiments in a model of type 1 diabetes.
Cardiovascular disease is the leading cause of death in the Western World. The company’s preliminary data shows that a single injection of HMGB1 leads to more than 50% improvement in heart function and similar reduction in damaged tissue in a mouse model.
Data has also shown that HMGB1 promotes regeneration if given up to 4 hours after injury. There is a huge commercial opportunity given that the average time for a person to reach a hospital in the USA following a heart attack is 3 hours.
Mutiple ongoing trials for products are going on that would reduce the autoimmune damage when it comes to diabetes. However, there is no current treatment that promotes beta cell regeneration yet.
The company also is focusing on Osteoarthritis, Parkinson’s Disease, and liver injury and additionally is working on obtaining data that will allow the company to file on novel composition of matter which will give them a unique molecule to progress to clinical trials.
The veterinary industry could also be a major market for the company as fractures of limbs are common in dogs and there is yet an approved product to accelerate healing.
Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN) will be working with PetCanna Pharma, a sister company, to develop a therapeutic for accelerating fracture healing in animals using Reformation IP. Regulatory hurdles are lower in veterinary medicine compared to humans so the company will be able to license the product for a quick financial return.
The biotech sector is comprised of several huge pharma companies that are developing CBD treatments in various delivery forms.
- GW Pharmaceuticals with Epidiolex
- Zynerba with a CBD “Patch” to treat refractory epilepsy, osteroarthritis, PTSD, and cancer related pain
- Axim Biotechnologies has CBD based chewing gums to treat several different conditions
- Insys Therapeutics has a sublingual CBD spray
- Nemus Bioscience is using various CBD extracts to treat glaucoma and other eye pathologies.
Last year there were several big takeovers in the biotech space including Gilead Sciences’ acquisition of Kite Pharma for $11.9 billion and Johnson & Johnson acquiring Actelion for $30 billion.
Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN) has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. This makes the company a viable candidate for takeover by large pharma players.
Disclaimer: Pursuant to an agreement between Resultz Media and Chasing Markets, we were hired to publicly disseminate information about (( RSCZF )) including on the Website and other media including Facebook and Twitter. We were paid $3,000 in cash from Resultz Media. We own zero shares of (( OTC: RSCZF )) which we purchased in the open market. We may buy or sell additional shares of ((OTC: RSCZF )) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
Source: Chasing Markets
Sponsored Content By: Resultz Media